Boehringer Ingelheim has announced WAC price reductions on Atrovent and Spiriva effective Jan. 1, 2025. This comes in addition to Merck’s recent announcement on Januvia, Janumet and Janumet XR. As with the Merck price reductions, any remaining inventory of the products will lose up to 40 percent of its value overnight.
To avoid unnecessary financial loss on these products, we recommend you:
-
Return any excess inventory on these products immediately.
-
Move to “on-demand inventory” on these items until Jan. 1, only ordering them when there’s an adjudicated claim to fulfill.
-
Inform patients using these products to call two days in advance for a refill.
-
Please check with your primary wholesaler for details on existing inventory returns.
Cardinal announced they will not accept returns on these products after Dec. 1, 2024. McKesson previously has allowed returns up to 30 days before WAC reductions, which would also be Dec. 1.
Merck announced a limited time “inventory stock adjustment program.” For more information contact the Merck National Service Center at (800) 672-6372.
And Boehringer Ingelheim has a limited rebate program for purchase between Dec. 15 and Dec. 28. For more information you can contact them at (203) 798-9988.
Wholesalers may make future WAC price reductions, so we recommend you keep a close eye on your wholesaler communications. We’ll continue providing updates as we receive them. For more information on the Merck WAC price reductions, click here.
Earlier this year, NCPA hosted a webinar to discuss the potential implications of upcoming WAC decreases and strategies for managing patient needs during the transition. The recording can be accessed here.
